We are live on ! Find out more
FTXH icon

First Trust Nasdaq Pharmaceuticals ETF

25 hedge funds and large institutions have $12.9M invested in First Trust Nasdaq Pharmaceuticals ETF in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

8.41% less ownership

Funds ownership: 55.38%46.98% (-8.4%)

19% less funds holding

Funds holding: 3125 (-6)

29% less capital invested

Capital invested by funds: $18.1M → $12.9M (-$5.16M)

30% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 10

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

Holders
25
Holders Change
-6
Holders Change %
-19.35%
% of All Funds
0.39%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
7
Reduced
10
Closed
8
Calls
Puts
Net Calls
Net Calls Change

FTXH Hedge Fund Activity: Q2 2023 in Review

25 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q2 2023, worth a combined $12.9M — down 29% from $18.1M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of FTXH and 2 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 7 added.

The largest buyer was Old Mission Capital, opening a new position worth an estimated $573K. The largest seller was Steward Partners Investment Advisory, cutting an estimated $1.78M.

  • 25 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q2 2023, down from 31 in Q1 2023.
  • Funds reported $12.9M of First Trust Nasdaq Pharmaceuticals ETF stock for Q2 2023, down 29% quarter-over-quarter.
  • 2 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q2 2023 and 8 closed out, a net change of -6 holders.
  • The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q2 2023 was Old Mission Capital, an estimated $573K added.
  • The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q2 2023 was Steward Partners Investment Advisory, an estimated $1.78M sold.

Based on aggregated 13F filings for Q2 2023.